Загрузка...

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. In conjunction wi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Anderson, Mary Ann, Deng, Jing, Seymour, John F., Tam, Constantine, Kim, Su Young, Fein, Joshua, Yu, Lijian, Brown, Jennifer R., Westerman, David, Si, Eric G., Majewski, Ian J., Segal, David, Heitner Enschede, Sari L., Huang, David C. S., Davids, Matthew S., Letai, Anthony, Roberts, Andrew W.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2016
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4920022/
https://ncbi.nlm.nih.gov/pubmed/27069256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-01-688796
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!